The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Central Nervous System Therapeutics Market From 2026 To 2030?
The central nervous system therapeutics market has experienced significant expansion in recent years. It is projected to increase from $134.99 billion in 2025 to $147.29 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. This historical growth can be attributed to the rising prevalence of depression and epilepsy, an expanding aging demographic, the restricted availability of treatments for degenerative disorders, an uptick in hospitalization rates for CNS conditions, and the development of hospital and clinic infrastructure.
The central nervous system therapeutics market size is projected to undergo significant expansion in the coming years, reaching $206.68 billion by 2030 with a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is primarily driven by the development of novel neuroprotective agents, the rise in biologics and gene-based therapies, heightened investment in neuroscience research, the increasing embrace of personalized medicine, and the broader availability of CNS treatments in emerging markets. Noteworthy trends anticipated in this period include the rising incidence of neurological and mental health disorders, a growing adoption of combination therapies for CNS conditions, an increased emphasis on long-term disease management and symptom alleviation, the expansion of homecare-based CNS treatment solutions, and improved drug formulations offering better blood-brain barrier penetration.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp
What Major Drivers Are Influencing Demand In The Central Nervous System Therapeutics Market?
The increasing occurrence of mental health conditions is anticipated to stimulate the future growth of the central nervous system therapeutics market. These disorders encompass a broad spectrum of conditions that impact an individual’s thinking, feeling, behavior, or mood, including examples like depression, anxiety disorders, schizophrenia, and bipolar disorder. The rising frequency of mental health disorders is attributed to increased exposure to chronic stress, which can impair emotional regulation, weaken coping mechanisms, and contribute to conditions such as anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics aid in treating mental health disorders by targeting brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, in December 2025, a report published by the Bristol City Council, a UK-based local government authority, revealed that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, indicating a 6.0% rise from 2021-22. Consequently, the growing prevalence of mental health disorders is propelling the central nervous system therapeutics market’s expansion.
Which Segments Are Included In The Analysis Of The Central Nervous System Therapeutics Market?
The central nervous system therapeutics market covered in this report is segmented –
1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes
2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
4) By Application: Hospital, Clinic, Homecare, Other Applications
Subsegments:
1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics
2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents
3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids
4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives
5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief
6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents
Which Trends Are Impacting The Growth Of The Central Nervous System Therapeutics Market?
Companies operating in the central nervous system therapeutics market are prioritizing innovative solutions like capsid engineering to improve targeted gene delivery, therapeutic effectiveness, and blood-brain barrier penetration for better treatment of neurological disorders. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), used in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, introduced coAAV CSF 01, a novel adeno associated virus (AAV) for central nervous system (CNS) delivery utilizing their proprietary ALIGATER platform. It demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Notably, equivalent expression levels to AAV9 were attained at just one-fifth of the dose, underscoring its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results highlight the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.
Which Key Industry Participants Are Active In The Central Nervous System Therapeutics Market?
Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.
Read the full central nervous system therapeutics market report here:
Which Region Shows The Strongest Potential For Future Growth In The Central Nervous System Therapeutics Market?
North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Central Nervous System Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27249&type=smp
Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2026, By The Business Research Company
Insurance Business Process Outsourcing Market Report 2026
Outsourced Customer Care Services Market Report 2026
Outsourced Software Testing Services Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model